# EDGAR Filing Document

**Accession Number:** 0001662579
**File Stem:** 0001628280-26-045194
**Filing Date:** 2026-6
**Character Count:** 9647
**Document Hash:** 09179f3237847ffed8ab83e01078e638
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-045194.hdr.sgml**: 20260624

**ACCESSION NUMBER**: 0001628280-26-045194

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260624

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260624

**DATE AS OF CHANGE**: 20260624

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** C4 Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001662579
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475617627
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39567
- **FILM NUMBER:** 261116140

**BUSINESS ADDRESS:**
- **STREET 1:** 490 ARSENAL WAY
- **STREET 2:** SUITE 120
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** (617) 231-0700

**MAIL ADDRESS:**
- **STREET 1:** 490 ARSENAL WAY
- **STREET 2:** SUITE 120
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

?xml version='1.0' encoding='ASCII'? cccc-20260624

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

_________________________________________________________________

**FORM 8-K**

_________________________________________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 24, 2026**

_________________________________________________________________

**C4 THERAPEUTICS, INC.**

**(Exact name of Registrant as Specified in Its Charter)**

_________________________________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39567** | **47-5617627** |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |
| **490 Arsenal Way, Suite 120**<br>**Watertown, MA** | | **02472** |
| **(Address of Principal Executive Offices)** | | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code: (617) 231-0700**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

_________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | CCCC | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 24, 2026, C4 Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders considered and voted on the four proposals set forth below, each of which is described in greater detail in the Company's definitive proxy statement on Schedule 14A, which was filed with the U.S. Securities and Exchange Commission on April 29, 2026. The final voting results are set forth below.

a) The stockholders of the Company elected each of Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors, to hold office until the 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified or until his earlier resignation or removal. The results of the stockholders' vote with respect to the election of the Class III directors were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **For** | **Withheld** | **Broker Non-Votes** |
| Andrew J. Hirsch | 47,797,964 | 8,247,406 | 21,049,125 |
| Stephen Fawell, Ph.D. | 47,811,414 | 8,233,956 | 21,049,125 |
| Utpal Koppikar | 46,491,892 | 9,553,478 | 21,049,125 |

---

b) The stockholders of the Company cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers. The results of the stockholders' vote with respect to this proposal were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 54,935,574 | 1,070,926 | 38,870 | 21,049,125 |

---

c) The stockholders of the Company ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders' vote with respect to this ratification proposal were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 76,891,210 | 185,427 | 17,858 | 0 |

---

d) The Company's stockholders approved an amendment to the Company's 2020 Stock Option and Incentive Plan to amend the evergreen provision to include any outstanding pre-funded warrants in the total number of shares of common stock that are issued and outstanding as of each December 31 for purposes of calculating the evergreen increase. The results of the stockholders' vote with respect to this proposal were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 33,713,572 | 22,287,787 | 44,011 | 21,049,125 |

---

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.

**Item 9.01 Financial Statements and Exhibits.**

(d) <u>Exhibits</u>. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 10.1# | <u>[Amendment No. 2 to the C4 Therapeutics, Inc. 2020 Stock Option and Incentive Plan](c4t-amendment2to2020stoc.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

# Indicates a management contract or any compensatory plan, contract or arrangement.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | C4 Therapeutics, Inc. | C4 Therapeutics, Inc. |
| Date: June 24, 2026 | By: | /s/ Kendra R. Adams |
|  |  | **Kendra R. Adams** |
|  |  | **Chief Financial Officer and Treasurer** |

---

## Exhibit 10.1

![](c4t-amendment2to2020stoc001.jpg)

Amendment No. 2 to the 2020 Stock Option and Incentive Plan In accordance with Section 16 of C4 Therapeutics, Inc. (the "Company") 2020 Stock Option and Incentive Plan (the "Plan"), the Plan is hereby amended as follows, subject to approval of the Company's stockholders: 1. Section 1 of the Plan is hereby amended to include the following as a new definition: "Outstanding Shares" means, as of a specified date, the sum of (a) number of shares of Stock issued and outstanding and (b) the number of Shares issuable pursuant to the exercise of any outstanding, pre-funded warrants to acquire Shares for a nominal exercise price. 2. The first sentence of Section 3(a) of the Plan is hereby deleted and replaced as follows: (a) Stock Issuable. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 6,567,144 shares (the "Initial Limit"), subject to adjustment as provided in Section 3(c), plus on January 1, 2021 and each January 1 thereafter, the number of shares of Stock reserved and available for issuance under the Plan shall be cumulatively increased by the lesser of (i) five percent (5%) of the Outstanding Shares on the immediately preceding December 31 or (ii) such lesser number of shares as determined by the Administrator (the "Annual Increase"). This Amendment No. 2 to the Plan (this "Amendment") constitutes an integral part of the Plan. For all purposes of this Amendment, capitalized terms used herein without definition shall have the meanings specified in the Plan, as the Plan shall be in effect on the date hereof after giving effect to the Amendment. Except as set forth herein, all of the terms and conditions of the Plan, as in effect prior to the effectiveness of this Amendment, shall continue to remain in full force and effect as originally stated therein. DATE APPROVED BY BOARD OF DIRECTORS: April 21, 2026

------